Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
71
NVSEF Quote, Financials, Valuation and Earnings
Last price:
$154.88
Seasonality move
:
5.89%
Day range:
$154.88 - $161.50
52-week range:
$97.30 - $171.29
Dividend yield:
2.88%
P/E ratio:
23.03x
P/S ratio:
5.90x
P/B ratio:
6.82x
Volume:
490
Avg. volume:
268K
1-year change:
38.99%
Market cap:
$314.6B
Revenue:
$54.5B
EPS (TTM):
$7.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVSEF
Novartis AG
|
$13.6B | -- | 1.95% | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
$154.5M | -- | -- | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVSEF
Novartis AG
|
$154.88 | -- | $314.6B | 23.03x | $4.74 | 2.88% | 5.90x |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
CSBTF
Kuros Biosciences Ltd.
|
$27.79 | -- | $1.1B | 451.14x | $0.00 | 0% | 7.47x |
|
ELVAF
EvoNext Holdings SA
|
$1.1700 | -- | $8.4M | 5.90x | $0.00 | 0% | 0.61x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$19.60 | -- | $254.2M | 1.45x | $0.00 | 0% | 4.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVSEF
Novartis AG
|
43.4% | 0.449 | 13.41% | 0.75x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 1.032 | -- | 2.96x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.122 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.069 | -- | -- |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -1.767 | -- | 0.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVSEF
Novartis AG
|
$9.8B | $3.5B | 18.45% | 32.34% | 26.4% | $1.1B |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
Novartis AG vs. Competitors
-
Which has Higher Returns NVSEF or BPMUF?
Basilea Pharmaceutica AG has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.34% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital NVSEFNovartis AG73.44% $1.25 $81.9B BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About NVSEF or BPMUF?
Novartis AG has a consensus price target of --, signalling downside risk potential of -46.41%. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Novartis AG has higher upside potential than Basilea Pharmaceutica AG, analysts believe Novartis AG is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings NVSEFNovartis AG0 0 0 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is NVSEF or BPMUF More Risky?
Novartis AG has a beta of 0.537, which suggesting that the stock is 46.256% less volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.449%.
-
Which is a Better Dividend Stock NVSEF or BPMUF?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 2.88%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 61.77% of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVSEF or BPMUF?
Novartis AG quarterly revenues are $13.3B, which are larger than Basilea Pharmaceutica AG quarterly revenues of --. Novartis AG's net income of $2.4B is higher than Basilea Pharmaceutica AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 23.03x while Basilea Pharmaceutica AG's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.90x versus 3.46x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSEFNovartis AG5.90x 23.03x $13.3B $2.4B BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- --
-
Which has Higher Returns NVSEF or CSBTF?
Kuros Biosciences Ltd. has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.34% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital NVSEFNovartis AG73.44% $1.25 $81.9B CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About NVSEF or CSBTF?
Novartis AG has a consensus price target of --, signalling downside risk potential of -46.41%. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Novartis AG has higher upside potential than Kuros Biosciences Ltd., analysts believe Novartis AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVSEFNovartis AG0 0 0 CSBTFKuros Biosciences Ltd.0 0 0 -
Is NVSEF or CSBTF More Risky?
Novartis AG has a beta of 0.537, which suggesting that the stock is 46.256% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 1.022, suggesting its more volatile than the S&P 500 by 2.244%.
-
Which is a Better Dividend Stock NVSEF or CSBTF?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 2.88%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 61.77% of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVSEF or CSBTF?
Novartis AG quarterly revenues are $13.3B, which are larger than Kuros Biosciences Ltd. quarterly revenues of --. Novartis AG's net income of $2.4B is higher than Kuros Biosciences Ltd.'s net income of --. Notably, Novartis AG's price-to-earnings ratio is 23.03x while Kuros Biosciences Ltd.'s PE ratio is 451.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.90x versus 7.47x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSEFNovartis AG5.90x 23.03x $13.3B $2.4B CSBTFKuros Biosciences Ltd.7.47x 451.14x -- --
-
Which has Higher Returns NVSEF or ELVAF?
EvoNext Holdings SA has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.34% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVSEFNovartis AG73.44% $1.25 $81.9B ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About NVSEF or ELVAF?
Novartis AG has a consensus price target of --, signalling downside risk potential of -46.41%. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Novartis AG has higher upside potential than EvoNext Holdings SA, analysts believe Novartis AG is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings NVSEFNovartis AG0 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is NVSEF or ELVAF More Risky?
Novartis AG has a beta of 0.537, which suggesting that the stock is 46.256% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -34.970, suggesting its less volatile than the S&P 500 by 3597.022%.
-
Which is a Better Dividend Stock NVSEF or ELVAF?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 2.88%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 61.77% of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVSEF or ELVAF?
Novartis AG quarterly revenues are $13.3B, which are larger than EvoNext Holdings SA quarterly revenues of --. Novartis AG's net income of $2.4B is higher than EvoNext Holdings SA's net income of --. Notably, Novartis AG's price-to-earnings ratio is 23.03x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.90x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSEFNovartis AG5.90x 23.03x $13.3B $2.4B ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns NVSEF or SPHDF?
Santhera Pharmaceuticals Holding AG has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.34% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.
Company Gross Margin Earnings Per Share Invested Capital NVSEFNovartis AG73.44% $1.25 $81.9B SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M -
What do Analysts Say About NVSEF or SPHDF?
Novartis AG has a consensus price target of --, signalling downside risk potential of -46.41%. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Novartis AG has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe Novartis AG is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings NVSEFNovartis AG0 0 0 SPHDFSanthera Pharmaceuticals Holding AG0 0 0 -
Is NVSEF or SPHDF More Risky?
Novartis AG has a beta of 0.537, which suggesting that the stock is 46.256% less volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.778, suggesting its less volatile than the S&P 500 by 177.839%.
-
Which is a Better Dividend Stock NVSEF or SPHDF?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 2.88%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 61.77% of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVSEF or SPHDF?
Novartis AG quarterly revenues are $13.3B, which are larger than Santhera Pharmaceuticals Holding AG quarterly revenues of --. Novartis AG's net income of $2.4B is higher than Santhera Pharmaceuticals Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 23.03x while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.90x versus 4.43x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSEFNovartis AG5.90x 23.03x $13.3B $2.4B SPHDFSanthera Pharmaceuticals Holding AG4.43x 1.45x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
60
SNSE alert for Apr 2
Sensei Biotherapeutics, Inc. [SNSE] is up 11.23% over the past day.
Sell
47
TAYD alert for Apr 2
Taylor Devices, Inc. [TAYD] is up 1.04% over the past day.
Sell
43
AXTI alert for Apr 2
AXT, Inc. [AXTI] is down 17.29% over the past day.
